# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CGEM: 23% | Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As...
The Dow Jones index closed lower by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their con...